Multiple Studies Presented at IDWeek 2018 Highlight Use of Karius Test as a Liquid Biopsy for Infectious Diseases
Academic collaborators presented results in challenging infectious disease applications including culture-negative endocarditis, predicting bloodstream infections in immunocompromised pediatric patients, and invasive fungal infections
REDWOOD CITY, Calif., Oct. 8, 2018 /PRNewswire-PRWeb/ -- Karius, a life sciences company transforming infectious disease diagnostics with genomics, today announced the results of several studies presented during this year's IDWeek conference for infectious diseases clinicians held last week in San Francisco, California. Clinical applications regarding use of the Karius® Test as a liquid biopsy for infectious diseases were the focus of the presentations. Oral abstracts, poster presentations and a Learning Lounge allowed collaborators to present their experiences with the Karius Test. Institutions represented were St. Jude Children's Research Hospital, Duke University, New York-Presbyterian Weill Cornell Medical Center, Florida Hospital Orlando, Ann & Robert H. Lurie Children's Hospital of Chicago, Stanford University, Children's National Medical Center, and The University of Florida.
"The data that Karius and our clinical study collaborators presented at IDWeek 2018 provide further evidence of the Karius Test's utility in diagnosing infections quickly and accurately in a variety of infectious disease applications," said Dr. David Hong, Vice President of Medical Affairs and Clinical Development at Karius. "The clinical studies presented by our colleagues cover some of the most challenging infectious diseases scenarios such as infective endocarditis, bloodstream infections in immunocompromised patients, invasive fungal infections, and febrile neutropenia."
Abstracts from studies of the Karius Test presented at IDWeek 2018 include:
Diagnosis and Genotyping of Coxiella burnetii Causing Endocarditis in a Patient with Prosthetic Pulmonary Valve Replacement (PVR) Using Next-Generation Sequencing (NGS) of Plasma
Presented by Dr. Maiko Kondo (Weill Cornell), Dr. Lars Westblade, Dr. Kristin Marks and Dr. Nell Eisenberg
Direct Detection and Quantification of Bacterial Cell-free DNA in Patients with Infective Endocarditis (IE) Using the Karius Plasma Next Generation Sequencing (NGS) Test
Presented by Pratik Shah (Duke) and Dr. Vance Fowler
Prediction of Bloodstream Infection Prior to Onset of Symptoms by Plasma Metagenomic Sequencing in Pediatric Patients with Relapsed or Refractory Malignancy (PREDSEQ)
Presented by Dr. Kathryn Goggin (St. Jude), Dr. Charles Gawad, and Dr. Josh Wolf
Posters presented include:
Diagnosis of BCG Aortitis by Plasma Metagenomic Sequencing
Presented by: Christopher D. Cooper, MD, Florida Hospital
Plasma Next-Generation Sequencing for Pathogen Detection in Pediatric Patients at Risk for Invasive Fungal Infection
Presented by: William J. Muller, MD, PhD, Ann & Robert H. Lurie Children's Hospital of Chicago
Evaluation of the Karius Plasma Next Generation Sequencing Cell-free Pathogen DNA Test to Determine the Etiology of Infection and Impact on Anti-Microbial Management in Patients with Severe Neutropenia and Fever
Presented by: Esther Benamu, MD, University of Colorado
In collaboration with Jose G. Montoya, MD and Stan Deresinski, MD, Stanford University
Streptococcus pneumoniae-related hemolytic uremic syndrome (pHUS) and the identification of matched cross country serotypes by plasma next-generation sequencing (NGS)
Presented by: Alexandra Yonts, MD and Ben Hanisch, MD, Children's National Medical Center
In collaboration with Lauge Farnaes, MD, PhD, Rady Children's Hospital, San Diego, CA
The company also hosted a learning lounge session: The Karius NGS Test: Liquid Biopsy for Infectious Diseases
Presented by: Dr. Christopher D. Cooper (Florida Hospital), Dr. Kenneth H. Rand (University of Florida), Dr. William J. Muller (Ann & Robert H. Lurie Children's Hospital) and Dr. David K. Hong (Karius).
About IDWeek
ID Week is an annual scientific meeting where infectious disease professionals can meet, share experiences, and develop collaborations. The meeting provides healthcare professionals with access to the latest infectious disease research as well as new innovative practices.
About the Karius Test
The Karius Test combines advanced genomic diagnostics for pathogen detection with expansive microbial data analytics and a rapid computational platform. The test enables clinicians to rapidly diagnose over 1,000 pathogens from a single, non-invasive blood test and obtain clinically actionable insights with next-day results for approximately 80% of specimens received by 8:30 am Monday to Saturday.
About Karius, Inc.
Karius is a life sciences company focused on transforming infectious disease diagnosis through the innovative use of next-generation sequencing to analyze microbial cell-free DNA. The Karius laboratory is CLIA-certified and CAP-accredited to perform high-complexity clinical laboratory testing. The company's genomics platform and clinically-curated pathogen database deliver deep insight into the microbial landscape, providing clinicians with a comprehensive, quantitative test capable of identifying more than a thousand pathogens directly from blood. For more information, visit kariusdx.com and follow us on Twitter at @kariusdx.
SOURCE Karius
Share this article